AUSTIN, Texas - Natera, Inc. (NASDAQ: NTRA), a genetic testing company valued at $22.5 billion and showing remarkable market performance with a 173% gain year-to-date, has broadened its patent infringement litigation against NeoGenomics (NASDAQ:NEO), Inc., involving the RaDaR assay, a test for molecular residual disease. The District Court for the Middle District of North Carolina recently allowed the inclusion of an additional patent, U.S. Patent No. 11,319,596, in the ongoing lawsuit. This is in addition to U.S. Patent No. 11,530,454, which was already part of the initial complaint.
The legal action follows previous court decisions, including a December 2023 preliminary injunction and a September 2024 permanent injunction against NeoGenomics' earlier version of the RaDaR test. Natera is seeking comprehensive remedies, including injunctive relief against NeoGenomics' current RaDaR test offering.
Natera specializes in cell-free DNA and genetic testing, focusing on areas such as oncology, women's health, and organ health. The company supports the integration of personalized genetic testing into standard care to enhance early and targeted interventions for better health outcomes. According to InvestingPro data, Natera demonstrates strong financial fundamentals with 55% revenue growth and a healthy current ratio of 4.4, indicating solid liquidity. Natera's tests have been substantiated by over 250 peer-reviewed publications, and the company operates certified laboratories in Austin, Texas, and San Carlos, California.
The company's press release includes forward-looking statements that are subject to risks and uncertainties, which may cause actual results to differ from expectations. These statements are based on information available as of the date of the press release, and Natera does not undertake any obligation to update them. The potential risks include developments in ongoing litigation and challenges related to the company's intellectual property rights. For a deeper understanding of Natera's financial health and growth prospects, investors can access comprehensive analysis and 14 additional ProTips through InvestingPro's detailed research reports.
This news report is based on a press release statement from Natera, Inc. and does not include any speculative content or opinions on the legal proceedings or the potential outcomes.
In other recent news, Natera Inc (NASDAQ:NTRA). has reported a record Q3 revenue of $439.8 million, marking a 64% increase year-over-year, and conducted 137,000 oncology tests, a 54% increase from the previous year. The company's gross margins reached a record high of 62%, leading to a revision of its full-year revenue guidance to between $1.61 billion and $1.64 billion. Amid these developments, TD Cowen reiterated a Buy rating on Natera shares, raising the price target from $175 to $195, reflecting confidence in the company's future performance. Similarly, Baird and Jefferies also maintained favorable ratings on Natera's stock and raised their price targets.
In terms of company news, Natera faced a setback in a false advertising lawsuit against Guardant Health (NASDAQ:GH), but plans to request the court to overturn the ruling. Furthermore, the company has amended an agreement with Dr. Rabinowitz, the Executive Chairman, to continue his role with conditions outlined in the agreement. These recent developments provide investors with a comprehensive view of Natera's current status and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.